Polypeptide With Localisation/Targeting Motif TRIZ Cases

This case combines CD19 and CD22 CARs to improve targeting, persistence, and functionality in engineered immune cells.

Recombinant yeast supplies cell-associated enzymes, reducing reliance on costly baking additives.

This case fuses antigen fragments with Sbi domains that bind complement C3d, enhancing immunogenicity for broadly neutralizing vaccines.

Fc point mutations and enhanced sialylation support FcRn recycling, improving ENPP1-Fc persistence against pathological calcification.

This case combines CAR-targeted Tregs with neuroprotective molecules to address pathogenic proteins, inflammation, and neuronal loss.

This case uses localized IL-18 mutations to preserve IL-18R binding while reducing IL-18BP neutralization and sustaining signaling.

Peptide sorting motifs guide ChR2 and HaloR to RGC subcellular regions, recreating center-surround receptive fields for signal processing.

This case uses REST phosphomimetic peptides for CTDSP1 binding, reducing REST protein levels and promoting neural gene expression.

This case uses 5–24 hours of IL-2 incubation to increase LDL-R 4.7–11-fold, supporting transduction without activation.

A CRISPR interference system uses a repressor fusion peptide to enhance gene silencing efficacy.

Transgenic silkworms produce active antibodies via silk gland secretion, avoiding mammalian costs and microbial insolubility.

Recombinant Nipah virus F ectodomain trimers use amino acid substitutions to stabilize prefusion conformations and enhance vaccine immunogenicity.

Mutating the N277SEGE281 sequence in CRY2 reduces the light threshold required for dimerization, resolving high irradiation constraints.

Self-limiting AAV vectors incorporate nuclease recognition sequences to enable targeted cleavage of the viral genome upon expression.

Recombinant TAGLN2 protein stabilizes actin polymerization to overcome insufficient costimulation and improve cytotoxic activity against solid tumors.

Inactivating CD38 on allogeneic immune cells prevents host rejection and graft-versus-host disease during cancer immunotherapy.

Replacing traditional T cell signaling domains with B cell or macrophage variants reduces basal signaling states and prevents T cell exhaustion in solid tumors.

Segmenting large polynucleotides across multiple vectors overcomes packaging limits while ligand-controlled assembly restores function in target immune cells.

Engineered IPD102 polypeptides expand pest control coverage beyond narrow Bt spectra while reducing environmental pollution from synthetic chemicals.

Transplanting allogeneic T-cell precursors eliminates graft-versus-host disease risk while enabling universal donor availability.

A chimeric antigen receptor redirects T cells to target CCR4-expressing malignancies using a specific single-chain variable fragment.

A fusion antigen comprising a ligand moiety and KDEL sequence directs viral proteins to antigen-presenting cells.

Segmented CAR T cell therapy targets CD123 to overcome rapid relapse in Blastic Plasmacytoid Dendritic Cell Neoplasm.

RP215 chimeric antigen receptor targets CA215 on cancer cells, inducing apoptosis and overcoming immune evasion through specific T cell activation.

Variant IGF2 peptides increase cellular uptake of therapeutic proteins by enhancing CI-MPR affinity while reducing off-target insulin receptor binding.

TALEN-cytidine deaminase fusion proteins convert target nucleotides in plant genomes.

Fusion proteins recruit the Hsp70 chaperone system to restore mutant p53 function, correcting conformational defects without harming normal cells.

Polypeptide systems use drug-controlled peptide docking domains to constrain recombinase activity, reducing leaky behavior and toxicity in cellular therapies.

Removing a cysteine residue from the overlap region of a TRAIL-R2-Fc fusion protein enhances stability under pH, thermal, and light stress conditions.

Cell-penetrating peptide fusion proteins boost botulinum toxin cellular uptake, raising the therapeutic index while reducing toxicity.

Modifying the cytoplasmic tail and transmembrane domain of the spike protein reduces membrane fusion, yielding a 40-fold increase in viral titre.

A multi-valent polypeptide stimulates adaptive immune responses through cytokine release.

Segmented DNA binding proteins fused with activation domains boost Klotho levels while preventing off-target effects.

Synthetic peptides target thrombus via molecular recognition, delivering anticoagulants directly to reduce off-target side-effects.

Hybrid signal peptides boost polypeptide production yield by resolving secretion efficiency limits in Gram-positive hosts.

Cleavable Lucy tags enable olfactory receptor trafficking to cell surfaces, resolving retention in the endoplasmic reticulum.

Fusing aMTDs with Cre recombinase overcomes protein aggregation and low solubility to enable efficient gene editing.

CARs targeting NPM1c neoepitopes eliminate cancer cells without harming normal tissues.

Tracking circulating tumor DNA via deep sequencing identifies somatic mutations, enabling non-invasive patient selection and response monitoring.

Bispecific antibody fragments combine amyloid-beta targeting with C1q activation to clear protein aggregates while controlling inflammatory responses.

Local quality targeting of extracellular matrix protein splice variants reduces on target off cancer toxicity while enhancing therapeutic efficacy.

Force-dependent cleavage of a fusion protein releases an intracellular degradation domain upon antigen binding, eliminating toxic small molecules.

Humanized anti-CD19 antibodies combine mouse variable regions with human constant domains to target CD19-positive tumors.